Immunosuppressive therapy: New concepts

Surgical Clinics of North America

Volumn 79, Issue 1, 1999, Pages 59-76

  Jain, A ^a   Khanna, A ^a   Molmenti, E P ^a   Rishi, N ^a   Fung, J J ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREQUINAR; CYCLOSPORIN A; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 1; CYCLOSPORIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID;

GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; HUMAN; IMMUNOLOGY; KIDNEY TRANSPLANTATION; LIVER; METABOLISM;

ANTIBODIES, MONOCLONAL; CYCLOSPORINE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LIVER; LIVER TRANSPLANTATION; MYCOPHENOLIC ACID; RECEPTORS, INTERLEUKIN-2; TACROLIMUS;

EID: 0033073903     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70007-4     Document Type: Article

References (160)

1. A.K. Abbas A.H. Lichtman J.S. Pober Immunity to tissue transplants Abbas A.K. Lichtman A. Pober J.S. Cellular and Molecular Immunology 1991 WB Saunders Philadelphia 335 352
2. Abu Elmagd K. J.J. Fung M. Alessiani The effect of graft function on FK506 plasma levels, doses, and renal function with particular reference to the liver Transplantation 51 1991 71 77
3. A.C. Allison S.J. Almquist C.D. Muller Immunosuppressive effects of mycophenolic acid and an ester pro-drug, RS-61443 Transplant Proc 23 1991 10 14
4. P.S. Almond A. Matas K. Gillingham Risk factors for chronic rejection in renal allograft recipients Transplantation 55 1993 752 757
5. W. Amend T. Soskin F. Vincenti Long-term experience in primary cadaver renal transplants using cyclosporine Clin Transplant 4 1990 341 346
6. J.M. Armitage F.J. Fricker Del Nido P. A decade (1982–1992) of pediatric cardiac transplantation and the impact of FK506 immunosuppression J Thorac Cardiovasc Surg 105 1993 464 472
7. J.M. Armitage F.J. Fricker Del Nido P. A decade (1982–1992) of pediatric cardiac transplantation and the impact of FK506 immunosuppression J Thorac Cardiovasc Surg 105 1993 464 472
8. J.M. Armitage R.L. Kormos J. Fung The clinical trial of FK506 as primary and rescue immunosuppression in adult cardiac transplantation Transplant Proc 23 1992 3054 3057
9. J.M. Armitage R.L. Kormos S. Morita Clinical trial of FK506 immunosuppression in adult cardiac transplantation Ann Thorac Surg 54 1993 205 211
10. C.L. Arteaga T.D. Brown J.G. Kuhn Phase I clinical and pharmacokinetic trial of brequinar sodium (DUP 785; NSC 368390) Cancer Res 49 1989 4648 4653
11. A. Atajima M. Hata N. Ohta Bredinin treatment in clinical kidney allografting Transplantation 38 1984 116 118
12. A.I. Benvenisty D. Cohen M.D. Stegall Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function Transplantation 40 1990 321 327
13. R.E. Billingham P.L. Krohn P.B. Medawar Effect of locally applied cortisone acetate on survival of skin homografts in rabbits Br Med J 2 1951 1049 1053
14. Bismuth H. European FK506 Multicenter Liver Study Group: Comparison of FK506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile Transplant Proc 27 1995 45 49
15. C. Boitard J.F. Bach Long-term complications on conventional immunosuppressive treatment Adv Nephrol 18 1989 335 354
16. C.M. Burke J. Theodore J.C. Baldwin Twenty eight cases of human heart-lung transplantation Lancet I 1986 517 519
17. J.F. Burke J.D. Pirsch E.L. Ramos Long-term efficacy and safety of cyclosporine in renal-transplant recipients N Engl J Med 331 1994 358 363
18. R.Y. Calne K. Rolles D.J.G. White Cyclosporine A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers Lancet II 1979 1033 1036
19. R.Y. Calne D.J. White S. Thiru Cyclosporine A inpatients receiving renal allografts from cadaver donors Lancet II 1978 1323 1327
20. R.Y. Calne Cyclosporine in cadaveric renal transplantation: 5 year follow up of a multicenter trial Lancet II 1987 506 507
21. R.Y. Calne Inhibition of the rejection of renal homografts in dogs by purine analogues Transplant Bull 26 1961 65 81
22. Canadian Multicenter Transplant Study Group A randomized clinical trial of cadaveric renal transplantation: Analysis at three years N Engl J Med 314 1986 1219 2125
23. Canadian Multicenter Transplant Study Group A randomized clinical trial of cyclosporine in cadaveric renal transplantation N Engl J Med 309 1983 809 815
24. L. Chatenoud M.F. Baudrihaaye N. Chkoff Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3 J Immunol 137 1986 830
25. G. Ciancio D. Roth F. Burke Renal transplantation in a new immunosuppressive era Transplant Proc 27 1995 812 813
26. Cooperative Clinical Trials in Transplantation Research Group Murine OKT4 immunosuppression in cadaver donor renal allograft recipients Transplantation 63 1997 1087 1095
27. R.J. Corry M.F. Egidi R. Shapiro Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients Transplant Proc 30 1998 512
28. R.J. Corry R. Shapiro M.F. Egidi Pancreas transplantation without antibody therapy Transplant Proc 30 1998 299 300
29. A. Cosimi R. Colvin R. Burton Use of monoclonal antibodies to T cell subsets for immunologic monitoring and treatment in recipients of renal allografts N Engl J Med 305 1981 308 314
30. D.V. Cramer F.A. Chapman B.D. Jaffee The effect of a new immunosuppressive drug, brequinar sodium, on heart, liver and kidney allograft in the rat Transplantation 53 1992 303 308
31. A.M. D'Alessandro M. Kalayoglu J.D. Pirsch FK506 rescue therapy for resistant rejection episodes in liver transplant recipients Transplant Proc 23 1991 2987
32. G.J. Dammin Prolonged survival of human-kidney homografts by immunosuppressive drug therapy N Engl J Med 268 1963 1315 1323
33. F.S. Darras M.L. Jordan R. Shapiro Transplantation of pediatric en bloc kidneys under FK506 immunosuppression Transplant Proc 23 1991 2089 2090
34. M.H. Deierhoi R.S. Kauffman S.L. Hudson Experience with mycophenolate mofetil (RS 61443) in renal transplantation at a single center Ann Surg 217 1993 476 482
35. A.J. Demetris J.J. Fung S. Todo FK506 used as rescue therapy for human liver allograft recipients Transplant Proc 23 1991 3005 3006
36. M.A. Dew R.C. Harris R.G. Simmons Quality-of-life advantage of FK506 vs conventional immunosuppressive drug therapy in cardiac transplantation Transplant Proc 23 1991 2061 2064
37. P. Donatsch E. Abisch M. Homberger A radioimmunoassay to measure cyclosporine A in plasma and serum samples J Immunoassay 2 1981 19 32
38. J. Dunn D. Golden Van Buren C.T. Causes of graft loss beyond two years in the cyclosporine era Transplantation 49 1990 349 353
39. European FK506 Multicenter Liver Study Group: Randomized trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection Lancet 344 1994 423 424
40. European Multicenter Trial Group Cyclosporine in cadaveric renal transplantation: Follow up at three years of a multicenter trial Transplant Proc 18 1986 1229 1233
41. European Multicenter Trial Group Cyclosporine in cadaveric renal transplantation: One year follow up of a multicenter trial Lancet II 1983 986 989
42. I. Felser S. Wagner J. Depree Changes in quality of life following the conversion from CyA to FK506 in orthotopic liver transplant patients Transplant Proc 23 1991 3032 3034
43. J.E. Foker R.L. Simmons J.S. Najarian Allograft rejection Najarian J.S. Simmons R.L. Transplantation 1972 Lea & Febiger Philadelphia 63 145
44. D.A. Fruman C.B. Lee B.E. Bierer Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporine A Proc Natl Acad Sci USA 89 1992 3686 3690
45. J.J. Fung K. Abu-Elmagd A.B. Jain A randomized trial of primary liver transplantation under immunosuppression with FK506 vs. cyclosporine Transplant Proc 23 1991 2977 2983
46. J.J. Fung M. Eliasziw S. Todo The Pittsburgh randomized trial of tacrolimus vs cyclosporine for liver transplantation J Am Coll Surg 183 1996 117 125
47. J.J. Fung S. Todo K. Abu-Elmagd Randomized trial in primary liver transplantation under immunosuppression with FK506 or cyclosporine Transplant Proc 25 1993 1130
48. J.J. Fung S. Todo A.B. Jain Conversion of liver allograft recipients with cyclosporine related complications from cyclosporine to FK506 Transplant Proc 22 1990 6 12
49. D.W. Gjertson J.M. Cecka P.I. Terasaki The relative effects of FK506 and cyclosporine on short and long term kidney graft survival Transplantation 60 1995 1384 1388
50. Griffin P.J.A. Gomes DaCosta C.A. J.R. Salaman Renal transplantation without steroids: A controlled clinical trial Transplant Proc 18 1986 797 798
51. B.P. Griffith K. Bando J.M. Armitage Lung transplantation at the University of Pittsburgh Terasaki P.I. Cecka J.M. Clinical Transplantation 1992 UCLA Tissue Typing Laboratory Los Angeles 149 159
52. B.P. Griffith K. Bando R.L. Hardesty A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation Transplantation 57 1994 848 856
53. B.P. Griffith R.L. Hardesty J.M. Armitage Acute rejection of lung allografts with various immunosuppressive protocols Ann Thorac Surg 54 1992 846 851
54. Gruessner RWG, FK506 Pancreatic Transplant Cooperative Study Group: Multicenter analysis of first experience with FK506 for induction and rescue therapy after pancreatic (PA) transplantation (Tx) [abstract I-2]. American Society of Transplant Surgeons, 21st Annual Scientific Meeting, Chicago, 33, May, 1995
55. M. Hakin D. Spiegelhalter T. English Cardiac transplantation with cyclosporine and steroids: Medium and long term results Transplant Proc 20 Suppl 3 1988 327 332
56. L. Hedman B. Frisk H. Brynger Severe kidney graft rejection in combined kidney and pancreas transplantation Transplant Proc 29 1987 3911 3912
57. A.D. Hess A.N. Esa P.M. Colombani Mechanisms of action of cyclosporine: Effect on cells of the immune system and on subcellular events in T cell activation Transplant Proc 20 Suppl 2 1988 29 40
58. M. Hourmat J. Bedrossian D. Durand A randomized multicenter trial comparing LFA-1 with rabbit antithymocyte globulin as induction treatment in first kidney transplantations Transplantation 62 1996 1565 1570
59. S. Iwatsuki T.E. Starzl S. Todo Experience in 1000 liver transplants under cyclosporine-steroid therapy: A survival report Transplant Proc 20 Suppl 1 1988 498 504
60. A.B. Jain J.J. Fung I. Hamad Use of mycophenolate mofetil for tacrolimus related chronic nephrotoxicity in liver transplantation recipients. American Association for the Study of Liver Diseases [abstract 427] Hepatology 29 1997 235A
61. A.B. Jain J.J. Fung S. Todo Incidence and treatment of rejection episodes in primary orthotopic liver transplantation under FK506 Transplant Proc 23 1991 931 933
62. A.B. Jain J.J. Fung S. Todo One thousand consecutive primary orthotopic liver transplants under FK506: Survival and adverse effects Transplant Proc 27 1995 1099 1104
63. A.B. Jain J.J. Fung Cyclosporine and tacrolimus in clinical transplantation Clin Immunother 5 1996 351 373
64. Jain AB, Hamad I, Rakela J, et al: A prospective randomized trial of tacrolimus and prednisone vs. tacrolimus, prednisone and mycophenolate mofetil in primary adult liver transplant recipients: An interim report. Transplantation, in press
65. A.B. Jain J. Reyes R. Kashyap Liver transplantation under tacrolimus in infants, children, adults and seniors: Long-term results: 1000 consecutive patients; survival and adverse events Transplant Proc 30 1998 1403 1404
66. A.B. Jain A. Singhal J.J. Fung Chronic rejection following primary adult liver transplantation under tacrolimus [abstract] Hepatology 29 1997 343A
67. A.B. Jain R. Venkataraman J.J. Fung Pregnancy after liver transplantation under tacrolimus Transplantation 64 1997 252 257
68. A.B. Jain R. Venkataramanan E. Cadoff Effect of hepatic dysfunction and T-tube clamping on FK506 pharmacokinetics and trough concentrations Transplant Proc 22 1990 57 59
69. A.B. Jain J.A.C. Buckles D. Adu Long-term results of cyclosporine renal transplantation from a single center Transplant Proc 20 2 Suppl 3 1988 82 85
70. C.W.B. Jensen M.L. Jordan F.X. Schneck Pediatric kidney transplantation under FK506 immunosuppression Transplant Proc 23 1991 3075 3077
71. M.L. Jordan R. Shapiro C.W.B. Jensen FK506 conversion of renal allografts failing cyclosporine immunosuppression Transplant Proc 23 1991 3078 3081
72. M.L. Jordan R. Shapiro C.A. Vivas FK506 salvage of renal allografts with ongoing rejection failing cyclosporine immunosuppression Transplant Proc 25 Book 1 1993 638 640
73. U. Jost M. Winkler B. Ringe FK506 treatment of intractable rejection after liver transplantation Transplant Proc 25 1993 2686 2687
74. B.D. Kahan J. Dunn C. Fitts The neoral formulation: Improved correlation between cyclosporine trough levels and exposure in stable renal transplant recipients Transplant Proc 26 1994 2940
75. Kahan BD, Rajagopalan PR, Hall ML, et al, on behalf of the US Simulect Study Group: Basilizimab is efficacious in reducing the incidence of acute rejection episodes in renal allograft patients: Results at 12 months [abstract 748]. In Program and Abstracts of the 17th Annual Meeting of the ASTP, Chicago, May 1998
76. B.D. Kahan N. Tejpal S. Gibbons-Stubbers The synergistic interactions in vitro and in vivo of brequinar sodium with cyclosporine or rapamycin alone and in triple combination Transplantation 55 1993 894 900
77. Kahan BD: Phase III trials: A phase III comparative efficacy trial of rapamune in renal allograft recipients [abstract 198]. The Rapamune US study Group. In Program and Abstracts of the 17th World Congress of The Transplantation Society, Montreal, July 1998
78. M.P. Kaye The Registry of the International Society for Heart and Lung Transplantation: Ninth official report J Heart Lung Transplant 11 1992 599 606
79. R.J. Keenan H. Konishsi A. Kawai Clinical trial of tacrolimus versus cyclosporine in lung transplantation Ann Thorac Surg 60 1995 580 585
80. T. Kino H. Hatanaka S. Miyata FK-506, a novel immunosuppressant isolated from a streptomyces: II. Immunosuppressive effect of FK506 in vitro J Anitbiot (Tokyo) 40 1987 1256 1265
81. A.D. Kirk D.M. Harlan N.N. Armstrong CTLA4-Ig and anti-CD40L ligand prevent allograft rejection in primates Proc Natl Acad Sci USA 94 1997 8789 8794
82. R.L. Kirkman M.E. Shapiro C.B. Carpenter A randomized trial of the anti-tac monoclonal antibody in human renal transplantation Transplantation 51 1991 107 113
83. J.M. Kriett M.P. Kaye The Registry of the International Society for Heart and Lung Transplantation: Eighth official report J Heart Lung Transplant 10 1991 491 498
84. C.P. Larsen E.T. Elwood D.Z. Alexander Long term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways Nature 381 1998 4334 4338
85. D.A. Laskow F. Vincenti J. Neylan Phase II FK506 multicenter concentration control study: One-year follow-up Transplant Proc 27 1995 809 811
86. H.A. Lee G. Slapak J. Venkataraman Mizoribine as an alternative to azathioprine in triple-therapy immunosuppressant regimens in cadaveric renal transplantation Transplant Proc 25 1993 2699 2700
87. Lewis R.M. Van Buren C.T. R.H. Kerman A review of long-term cyclosporine use in renal transplantation Clin Transplant 4 1990 313 320
88. Lewis R.M. Van Buren C.T. B. Radonancevic Impact of long-term cyclosporine immunosuppressive therapy on native kidneys versus renal allografts: Serial renal function in heart and kidney transplant recipients J Heart Lung Transplant 10 1991 63 70
89. W.D. Lewis R.L. Jenkins P.A. Burke FK506 rescue therapy in liver transplant recipients with drug-resistant rejection Transplant Proc 23 1991 1989
90. W.D. Lewis R.L. Jenkins P.A. Burke FK506 rescue therapy in liver transplant recipients with drug-resistant rejection Transplant Proc 23 1991 2989 2991
91. Liu J. J.D. Farmer Jr W.S. Lane Calcineurin is a common target of cyclosporine A and FKBP-FK506 complexes Cell 66 1991 807 815
92. F. Marumo M. Okubo K. Yokota A clinical study of renal transplant patients receiving triple-drug therapy—cyclosporine A, mizoribine, and prednisone Transplant Proc 20 1988 406 409
93. S.V. McDiarmid R.W. Busuttil N.L. Ascher FK506 (tacrolimus) compared with cyclosporin for primary immunosuppression after pediatric liver transplantation Transplantation 59 1995 530 560
94. S.V. McDiarmid G.B. Klintmalm R.W. Busuttil FK506 conversion for intractable rejection of the liver allograft Transplant Int 6 1993 305 312
95. J. Miller J.D. Pirsch M. Deierhoi FK506 in kidney transplantation: Results of the USA randomized comparative phase III study Transplant Proc 29 1997 304 305
96. K. Mita N. Akiyama T. Nagao Advantages of mizoribine over azathioprine in combination therapy with cyclosporine for renal transplantation Transplant Proc 22 1990 1679 1681
97. J.A. Morgan The influence of cortisone on the survival of homografts of skin in the rabbit Surgery 30 1951 506 515
98. Murgia MG, Jordan S, Kahan BD: The side effect of profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209–216, 196
99. J.E. Murray J.P. Merrill J.H. Harrison Prolonged survival of human-kidney homografts by immunosuppressive drug therapy N Engl J Med 268 1963 1315 1323
100. J.E. Murray Nobel Prize Lecture: First successful transplant in man Terasaki P.I. History of Transplantation: Thirty-Five Recollections 1991 UCLA Tissue Typing Laboratory Los Angeles
101. B. Nashan R. Moore P. Amlot Randomized trial of basilizimab versus placebo for control of acute rejection in renal allograft recipients Lancet 350 1997 1193 1197
102. T. Ochai K. Fukao K. Takahashi Japanese FK506 Study Group: Phase III study of FK506 in kidney transplantation Transplant Proc 27 1995 829 833
103. T. Ochai M. Ishibashi K. Fukao Japanese multicenter studies of FK506 in renal transplantation Transplant Proc 27 1995 50 56
104. K. Oldhafer G.W. Haller A. Kattner Absorption of cyclosporine Neoral early after liver transplantation: Influence of bile on oral absorption Transplant Proc 28 1996 2237
105. G. Opelz Effect of the maintenance immunosuppressive drug regimen on kidney transplant outcome Transplantation 58 1994 443 446
106. P.E. Oyer E.B. Stinson S.W. Jamieson Cyclosporine in cardiac transplantation: A two and a half year follow up Transplant Proc 15 1983 2564
107. S.M. Pham J.M. Armitage R.L. Kormos Rescue therapy with FK506 in cardiac transplantation Circulation 88 4 Pt 2 1993 I-94
108. S.M. Pham J.M. Armitage R.L. Kormos Rescue therapy with FK506 in cardiac transplantation Circulation 88 4 Pt 2 1993 I-94
109. J.D. Pirsch J. Miller M.H. Deierhoi A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaver renal transplantation Transplantation 63 1997 977 982
110. Platz K.-P. A.R. Mueller M. Zytowki OKT3 vs FK506 rescue management of acute steroid-resistant and chronic rejection Transplant Proc 27 1995 1111 1113
111. J.S. Radomski B.A. Ahlswede B.E. Jarrell Outcomes of 500 pregnancies in 335 female kidney, liver and heart transplant recipients Transplant Proc 27 1995 1089
112. J.S. Radomski M.J. Moritz S.J. Munoz National Transplantation Pregnancy Registry: Analysis of pregnancy outcomes in female liver transplant recipients Liver Transplant Surg 1 1995 281
113. R. Reding P.E. Wallemacq M.E. Lamy Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts: Efficacy, toxicity and dose regimen in 23 children Transplantation 57 1994 93 100
114. R. Reding P.E. Walmacq M.E. Lamy Conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts: Efficacy, toxicity and dose regimen in 23 children Transplantation 57 1994 93 100
115. J. Reyes A. Jain G. Mazariegos Conversion of pediatric liver allograft recipients from cyclosporine in tacrolimus based immunosuppression: 4 to 8 years follow up [abstract 177] Pediatr Transplant 2 1998 75
116. J. Reyes A. Jain G. Mazariegos Primary liver transplantation in children under tacrolimus: 3 to 8 years actual follow up [abstract 181] Pediatr Transplant 2 1998 76
117. Roche Laboratories: Cellcept (mycophenolate mofetil capsules): A member of the Roche Group. Nutley, NJ, Hoffman-La Roche,
118. P. Rucay D. Samuel O. Farges FK506 as treatment of late acute rejection in liver transplant patients Transplant Proc 27 1991 1105 1106
119. P. Rucay D. Samuel D. Gillet FK506 rescue therapy for refractory acute rejection in five liver recipients Transplant Proc 23 1991 3000 3001
120. D. Saloman M. Brunson J. Vansickler A retrospective analysis of late renal graft function: Correlation with mean cyclosporin levels and lack of evidence for chronic cyclosporin toxicity Transplant Proc 45 1988 913 918
121. V.P. Scantlebury R. Shapiro A. Tzakis Pediatric kidney transplantation at the University of Pittsburgh Transplant Proc 26 1994 46 47
122. S.L. Schreiber G.R. Crabtree The mechanisms of action of cyclosporine A and FK506 Immunol Today 13 1992 126
123. S.L. Schreiber Chemistry and biology of the immunophillins and the immunosuppressive ligands Science 251 1991 283 287
124. H.J. Schuurman S. Cottens S. Fuchs SDZ RAD, a new rapamycin derivative Transplantation 64 1997 32 35
125. R. Schwartz W. Dameshek The effects of 6-mercaptopurine on homograft reactions J Clin Invest 39 1960 952 958
126. R. Shapiro M. Jordan V. Scantlebury FK506 in clinical kidney transplantation Transplant Proc 23 1991 3065 3067
127. B.W. Shaw R. Markin R. Stratta FK506 for rescue treatment of acute and chronic rejection in liver allograft recipients Transplant Proc 23 1991 2994 2995
128. H.W. Sollinger F.O. Belzer M.H. Deierhoi RS-61443: Rescue therapy in refractory kidney transplant rejection Transplant Proc 25 1993 698 769
129. H.W. Sollinger F.O. Belzer M.H. Deierhoi RS-61443 (mycophenolate mofetil): A multicenter study for refractory kidney transplant rejection Ann Surg 216 1992 513 518
130. Sollinger HW for the US Renal Transplant Mycophenolate Mofetil Study Group Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients Transplantation 60 1995 225 232
131. T.E. Starzl A. Donna M. Eliasziw Randomized trialomania?: The multicenter liver transplant trials Lancet 346 1995 1346 1350
132. T.E. Starzl J. Fung M. Jordan Kidney transplantation under FK506 JAMA 264 1990 62 67
133. T.E. Starzl S. Iwatsuki Van Thiel D.H. Evolution of liver transplantation Hepatology 2 1982 614 636
134. T.E. Starzl S. Todo J.J. Fung FK506 for liver, kidney, and pancreas transplantation Lancet II 1989 1000 1004
135. T.E. Starzl T.L. Marchioro W.R. Waddel The reversal of rejection in human renal homografts with subsequent development of homograft tolerance Surg Gynecol Obstet 117 1963 385 395
136. R.J. Stratta A.M. D'Alessandro M.J. Armburst Sequential antilymphocyte globulin/cyclosporine immunosuppression in cadaveric renal transplantation: Effect of duration of ALG therapy Transplantation 47 1989 96 102
137. Subbotin VM, Sun H, Aitouche A, et al: Reversal of chronic rejection in mouse aortic allografts by combined treatment with CTLA4-Ig and ant-CD40L monoclonal antibody [abstract 692]. In Program and abstracts of the 16th annual Scientific Meeting of ASTP, Chicago, May 1997
138. S. Teraoka T. Babazono T. Koike Effect of rescue therapy using FK506 on relapsing rejection after combined pancreas and kidney transplantation Transplant Proc 27 1995 1335 1339
139. The European Multicenter Renal Transplant Mycophenolate Mofetil Study Group Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection Lancet 345 1995 1321 1325
140. The US Multicenter FK506 Liver Study Group: A comparison of tacrolimus (FK506) with cyclosporine for immunosuppression in liver transplantation N Engl J Med 331 1994 1110 1115
141. A.W. Thomson P.B. Carroll J. McCauly FK506: A novel immunosuppressant for treatment of autoimmune disease Springer Semin Immunopathol 14 1993 323 344
142. S. Todo J.J. Fung A.J. Demetris Early trials with FK506 as primary treatment in liver transplantation Transplant Proc 22 1990 13 16
143. S. Todo J.J. Fung T.E. Starzl Single center experience with primary orthotopic liver transplantation under FK506 immunosuppression Ann Surg 220 1994 297 330
144. S. Todo J.J. Fung A. Tzakis 110 consecutive primary orthotopic liver transplantation under FK506 Transplant Proc 23 1991 1399 1402
145. K.M. Tornator K.A. Reed R.C. Venuto Methylprednisolone and cortisol metabolism during the early post-renal transplant period Clin Transplant 9 1995 427 432
146. L.A. Turka J. Dayton G. Sinclair Guanine ribonucleotide depletion inhibits T cell activation: Mechanism of action of the immunosuppressive drug mizoribine J Clin Invest 87 1991 940 948
147. A. Tzakis J. Reyes S. Todo Two-year experience with FK506 in pediatric patients Transplant Proc 25 Book I 1993 619 621
148. United Network for Organ Sharing UNOS Update II 1995 34 40 http://www.unos.org
149. US Multicenter FK506 Study Group: Prognostic factors for successful conversion from cyclosporine to FK506-based immunosuppressive therapy for refractory rejection after liver transplantation Transplant Proc 25 1993 641 643
150. R. Venkataramanan A.B. Jain V.W. Warty Pharmacokinetics of FK506 following oral administration: A comparison of FK506 and cyclosporine Transplant Proc 23 1991 931 933
151. F. Vincenti R. Kirkman S. Light Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation N Engl J Med 338 1998 161 165
152. T.H. Waid B.A. Lucas J.S. Thompson Treatment of acute cellular rejection with T10B9.1A or OKT3 in renal allograft recipients Transplantation 53 1992 80 86
153. H. Wanger Cyclosporine A: Mechanism of action Transplant Proc 15 1983 523 526
154. K. Wengerten A.J. Matas V.A. Tellis Transplantation of pediatric donor kidneys to adult patients Ann Surg 204 1986 172 175
155. M. Winkler G. Haller K. Oldhafer A new oral formulation of cyclosporine for early oral immunosuppressive therapy in liver transplant recipients Transplantation 62 1996 1063
156. L.E. Wrenshall A.J. Matas D.M. Canafax An increased incidence of late acute rejection episodes in cadaver renal allograft recipients given azathioprine, cyclosporine, and prednisone Transplantation 50 1990 233 237
157. X.Y. Xu K. Honjo D. Devore-Carter Immunosuppression by inhibition of cellular adhesion mediated by leukocyte function-associated antigen-1/intercellular adhesion molecule-1 in murine cardiac Transplantation 63 1997 876 885
158. R.W. Yatscoff K.R. Copeland C.J. Farari Abbott Tdx monoclonal antibody assay evaluated for measuring cyclosporine in whole blood Clin Chem 36 1990 1969 1973
159. R.W. Yatscoff T.G. Rosano L.D. Bowers The clinical significance of cyclosporin metabolites Clin Biochem 24 1991 23 35
160. C.F. Zukoski H.M. Lee D.M. Hume The prolongation of functional survival of canine renal homografts by 6-mercaptopurine Surg Forum 11 1960 470 472